Ozempic Wars | The Next Injection | 2

This episode of Business Wars focuses on the competition between Novo Nordisk and Eli Lilly in the GLP-1 weight loss drug market. Following the FDA approval of Eli Lilly's ZepBound, a more effective weight loss drug, Novo Nordisk faces increasing pressure, including public scrutiny over drug pricing and supply chain issues. Eli Lilly gains market share through direct sales and lower-priced options, while Novo Nordisk struggles with production shortages and negative publicity. The episode details Novo Nordisk's attempts to counter Eli Lilly's moves, including partnerships and acquisitions, and concludes with an exploration of the potential long-term safety concerns and the future of the GLP-1 drug market.